Evidence-based strategies for screening, diagnosing and treating alcohol use disorders (AUD) are instrumental in the early and better management of individuals at risk for or suffering from AUD. However, existing guidelines vary and may be biased by conflicts of interests. Unbiased recommendations can be achieved only if sufficient detail is provided on the composition and representativeness of author groups, methodological rigor, handling of potential conflicts of interest and financing. This paper presents the first evidence-based guidelines for AUD from German-speaking countries. These guidelines are based on the work of delegates from a representative sample of 46 scientific societies (mostly medical) from Austria, Germany and Switzerland dealing with AUD. It also included patients and relatives. Recommendations were derived from a standardised hierarchical process involving quality controls drawn from existing guidelines, de novo literature searches and/or expert experience. Potential conflicts of interest were assessed yearly and led to exclusion from voting in specific areas. An overall cost of more than 400,000€ (for alcohol and tobacco guidelines) were exclusively covered by the participating societies and academic institutions. More than 100 recommendations on screening, diagnostics and treatment of AUD are outlined in this paper, and their scientific background is given in the online supplementary material. Tables of aggregated study synopses (in English) and the full version of guidelines (in German) are available (see “Links”).

Keywords:
Guideline, Screening, Diagnoses, Treatment, Alcohol use disorders, Evidence base
1.
Pabst A, Kraus L, Gomes de Matos E, Piontek D: Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013;59:321-331.
2.
Gärtner B, et al: Alkohol - Zahlen und Fakten zum Konsum. Jahrbuch Sucht 2013:36-66.
3.
Salize HJ, Jacke C, Kief S, Franz M, Mann K: Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years. Addiction 2013;108:62-70.
4.
Singer MV, Batra A, Mann K (Hrsg): Alkohol und Tabak. Grundlagen und Folgeerkrankungen. Stuttgart und New York, Thieme Verlag, 2011, pp 57-62.
5.
Rehm J, Rehm M, Shield KD, Gmel G, Frick U, Mann K: Reduzierung alkoholbedingter Mortalität durch Behandlung der Alkoholabhängigkeit [Decrease in alcohol-attributable mortality by treatment of alcohol dependents]. Sucht Zeitschrift für Wissenschaft und Praxis 2014;60:93-105.
6.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) - Ständige Kommission Leitlinien. AWMF-Regelwert “Leitlinien”. 1. Auflage 2012. Verfügbar. http://www.awmf.org/leitlinien/awmf-regelwert.html (August 5, 2016).
7.
Hoch E, Batra A, Mann K: Das S3-Leitlinienprogramm für substanzbezogener Störungen. Sucht 2012;2:14-25.
8.
Mann K, Hoch E, Batra A, Bonnet U, Günthner A, Reymann G, Soyka M, Wodarz N, Schäfer M: Leitlinienorientierte Behandlung alkoholbezogener Störungen [Guideline-oriented treatment of alcohol-related disorders]. Nervenarzt 2016;87:13-25.
9.
Scottish Intercollegiate Guidelines Network (SIGN): The management of harmful drinking and alcohol dependence in primary care. http://www.sign.ac.uk/guidelines (August 5, 2015).
10.
OCEBM Levels of Evidence Working Group: The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653 (August 10, 2015).
11.
Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV): Nationales Programm für Versorgungs-Leitlinien. Methoden-Report, 2014.
12.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) - Ständige Kommission Leitlinien. AWMF-Regelwerk “Leitlinien”. 1. Aufl. 2013. http://www.awmf.org/leitlinien/awmf-regelwerk.html (August 10, 2015).
13.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, et al; GRADE Working Group: Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-1498.
14.
Batra A, Petersen KU, Hoch E, Andreas S, Bartsch G, Gohlke H, Jähne A, Kröger C, Lindinger P, Mühlig S, Neumann T, Pötschke-Langer M, Ratje U, Rüther T, Schweizer C, Thürauf N, Ulbricht S, Mann K: S3 Guideline “Screening, diagnostics, and treatment of harmful and addictive tobacco use”. Sucht 2016;62:139-152.
15.
Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, Schäfer I, Beutel M, Mann KF, Hoch E: Psychische Komorbiditäten bei alkoholbedingten Störungen. Nervenarzt 2016;87:26-34.
16.
Sellman JD, Sullivan PF, Dore GM, Adamson SJ, MacEwan I: A randomized controlled trial of motivational enhancement therapy (MET) for mild to moderate alcohol dependence. J Stud Alcohol 2001;62:389-396.
17.
National Institute for Health and Care Excellence: Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence (CG 115). National Institute for Health and Clinical Excellence, 2011.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.